|Bid||0.00 x 900|
|Ask||0.00 x 800|
|Day's Range||31.63 - 35.54|
|52 Week Range||12.80 - 50.54|
|Beta (5Y Monthly)||2.17|
|PE Ratio (TTM)||N/A|
|Earnings Date||Mar 08, 2022 - Mar 14, 2022|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||53.88|
Biotech investors still like BioCryst, Protagonist, Prometheus Biosciences, Rani, and Emergent BioSolutions. All sported recent double-digit gains despite the sector slump.
In this article we will check out the progression of hedge fund sentiment towards Protagonist Therapeutics, Inc. (NASDAQ:PTGX) and determine whether it is a good investment right now. We at Insider Monkey like to examine what billionaires and hedge funds think of a company before spending days of research on it. Given their 2 and […]
Protagonist Therapeutics (Nasdaq: PTGX) ("Protagonist" or "the Company") today announced that Dinesh V. Patel, Ph.D., President and Chief Executive Officer, will present virtually at the 40th Annual J.P. Morgan Healthcare Conference on Tuesday, January 11 at 2:15 p.m. EST.